Search

Your search keyword '"Tajiri, Wakako"' showing total 21 results
Start Over Author "Tajiri, Wakako"
21 results on '"Tajiri, Wakako"'

4. A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report.

Author

Koi, Yumiko, Tajiri, Wakako, Kawasaki, Junji, Akiyoshi, Sayuri, Ijichi, Hideki, Nakamura, Yoshiaki, Koga, Chinami, Koga, Yutaka, Taguchi, Kenichi, and Tokunaga, Eriko

Abstract

We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46‐year‐old Japanese woman with primary metaplastic carcinoma of the breast, which was immunohistochemically confirmed to be triple‐negative breast cancer, underwent radical surgery, followed by adjuvant chemotherapy with an anthracycline and a taxane. Since multiple lung metastases were detected two months post‐chemotherapy and the primary site was shown to be PD‐L1‐positive, the immune checkpoint inhibitor (ICI) pembrolizumab plus gemcitabine/carboplatin was initiated. While the treatment was discontinued after 15 days due to suspected drug‐induced pneumonitis, the lung metastases significantly shrank with no development of new lesions for three months. The patient remained alive as of approximately 15 months after the recurrence date. This case highlights the potential of immunochemotherapy in treating metaplastic breast carcinomas. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Abstract P4-05-11: The clinical importance of the new category, ER low-positive in the ER expression HER2 negative early breast cancer

Author

Tajiri Wakako

Subjects
Cancer Research, Oncology, mental disorders
Abstract

In the latest updated ASCO/CAP guideline, a new category, ER low-positive was introduced, which are determined by the 1% to10 % of positive staining of the tumor nuclei for ER. However clinical meaning of ER-low positive was unclear compared with ER- positive or ER-negative in HER2 negative breast cancer. In order to clarify the clinicopathological features of ER-low positive breast cancer, we compared the clinicopathological factors and prognosis among three groups, ER negative, ER-low positive, and ER-positive groups in the patients with HER2 negative breast cancer. A total of 1,882 patients with HER2 negative breast cancer who underwent surgery between 2001 and 2018 were included in this study. We divided them into three groups, ER negative (According to ER status, 553(29.4%), 183(9.7%), 1146(60.9%) patients were divided into ER negative, low-positive and positive groups. Compared with ER-positive group, patients in the ER negative and low-positive groups were of higher age (p This study showed that the prognosis of the patients with ER negative and ER low-positive were similar, and poorer than that of those with ER positive tumors. Therefore, the new category of ER-low positive is clinically especially important in order to determine the appropriate adjuvant therapy. Citation Format: Tajiri Wakako. The clinical importance of the new category, ER low-positive in the ER expression HER2 negative early breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-11.

Published
2022

12. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

Author

Tajiri, Wakako, primary, Ijichi, Hideki, additional, Takizawa, Katsumi, additional, Koi, Yumiko, additional, Masuda, Takanobu, additional, Ueo, Hiroki, additional, Koga, Chinami, additional, Nakamura, Yoshiaki, additional, Taguchi, Kenichi, additional, Okamoto, Masahiro, additional, and Tokunaga, Eriko, additional

Published
2020
Full Text
View/download PDF

13. Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice

Author

OKAMOTO, MASAHIRO, primary, TAJIRI, WAKAKO, additional, UEO, HIROKI, additional, MASUDA, TAKANOBU, additional, IJICHI, HIDEKI, additional, KOGA, CHINAMI, additional, NAKAMURA, YOSHIAKI, additional, TAGUCHI, KENICHI, additional, OHNO, SHINJI, additional, and TOKUNAGA, ERIKO, additional

Published
2020
Full Text
View/download PDF

17. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy

Author

Tokunaga, Eriko, primary, Fujita, Aya, additional, Takizawa, Katsumi, additional, Baba, Kimiko, additional, Akiyoshi, Sayuri, additional, Nakamura, Yoshiaki, additional, Ijichi, Hideki, additional, Masuda, Takanobu, additional, Koga, Chinami, additional, Tajiri, Wakako, additional, Ohno, Shinji, additional, Taguchi, Kenichi, additional, and Ishida, Mayumi, additional

Published
2018
Full Text
View/download PDF

21. [Comparative Safety Study of Original and Generic Docetaxel without Alcohol in the Treatment of Breast Cancer].

Author

Hara M, Eto T, Ijichi H, Nakamura Y, Koga C, Tajiri W, Okamoto M, Tokunaga E, and Misumi N

Subjects
Humans, Female, Docetaxel adverse effects, Retrospective Studies, Taxoids adverse effects, Ethanol therapeutic use, Edema chemically induced, Edema drug therapy, Breast Neoplasms drug therapy, Peripheral Nervous System Diseases chemically induced, Antineoplastic Agents therapeutic use
Abstract

Docetaxel(DTX)is a key drug for breast cancer treatment; however, its formulation contains alcohol, which can cause several problems. We have been preparing original DTX without using its accompanying alcohol-solubilizing solution since 2013 and switched to generic DTX without alcohol in 2015. In this study, we compared adverse events between the original and generic DTX, both of which did not contain alcohol. We retrospectively investigated the occurrence of adverse events in breast cancer patients who were treated with DTX(75 mg/m2)as neoadjuvant or adjuvant chemotherapy from January 2013 to December 2017. 201 patients participated in the study(75/126 in the original/generic groups). The incidence of febrile neutropenia, hypersensitivity reactions, and skin toxicities did not differ between the groups(p=0.620, 0.066, 0.205). The severity of edema and peripheral neuropathy was significantly worse in the patients receiving the generic DTX (p<0.01, <0.01). The findings suggest a difference in the incidence of edema and peripheral neuropathy following treatment with the original and generic DTX, regardless of the inclusion of alcohol.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results